Nucleix Appoints Michael G. Vicari as Chief Commercial Officer Mr. Vicari to plan and lead the company’s commercialization of Lung EpiCheck®
06/06/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the...
Nucleix’s Bladder EpiCheck® Receives FDA 510(k) Clearance for Monitoring of Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence
04/05/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has received...
Nucleix to Premiere Data on its EpiCheck® Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting
13/04/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will premiere...
Nucleix Receives CAP Accreditation and CLIA Certification for its San Diego Clinical Laboratory
19/10/2022
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix Expands EU Label Indication of Bladder EpiCheck® to Include the Detection of Primary Bladder Cancer and Detection of Primary and Recurrent Upper Tract Urinary Cancer
22/06/2022
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
STAY UPDATED ON THE LATEST NEWS FROM NUCLEIX!
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “[email protected]”.
Click the confirmation link
Click on the link inside the
email and you’re good to go.